TABLE 1.
Anti-RSV activity of RSV L inhibitors
| Compound | Mean ± SD (n = 3 to 16) |
Selective index, CC50/EC50d | |||
|---|---|---|---|---|---|
| RSV EC50 (μM)a |
Replicon assay, EC50 (μM)b | Cytotoxicity assay, CC50 (μM)c | |||
| A2 | B-WST | ||||
| YM-53403 | 0.75 ± 0.31 | >20 | 1.2 ± 0.93 | >50 | NA |
| BI cpd D | 0.32 ± 0.04 | 0.25 ± 0.004 | 0.77 ± 0.21 | 9.3 ± 2.2 | 29 |
| AZ-27 | 0.01 ± 0.004 | 1.3 ± 0.89 | 0.05 ± 0.02 | >100 | >79 |
a
EC50 measured by RSV ELISA in HEp-2 cells following 3-day (A2) or 4-day (B-WST) RSV infection in the presence of compound.
b
EC50 measured by RSV replicon luciferase assay following 2-day compound treatment of BHK-based RSV A2 replicon cells.
c
CC50 measured by cytotoxicity assay in parallel with the EC50 assays.
d
Selective index calculated as the ratio between CC50 and EC50 of the A2 or B-WST ELISA; NA, not applicable.